FOXA vs SYRE · P/E 14, rev $17.13B vs $7.60B cap
Fox Corp Class A (FOXA) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
Fox Corp Class A (FOXA) is a entertainment company listed on US.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported FOXA revenue for 2026-06-30 was $17.13B. Net income was $1.73B. Revenue was up 5.1% from 2025-06-30 to 2026-06-30. FOXA currently screens at market cap $24.50B and trailing P/E 14.1.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
FOXA currently screens at market cap $24.50B and trailing P/E 14.1. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the FOXA and SYRE stock pages for the full models.
Not investment advice.